Google Übersetzer
Entrada Therapeutics, Inc.
About
6.63USD-0.07 -1.04%
Closed • Updated at 06:43 GMT+00:00Market Cap$257.38M
Volume426.5K
Beta-0.33
RSI33.05
Gross Margin30.45%
Entrada Therapeutics, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
May 7 2026
Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study
May 6 2026
Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026
Feb 26 2026
Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Feb 17 2026
Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
Feb 4 2026
Entrada Therapeutics to Present at Upcoming Investor Conferences
Recent Videos
$ENGN collapsed -81% — biggest stock losers today
May 07, 2026
¡CAOS EN LA FDA Y DERRUMBES DEL 80%! Atara resucita, enGene se desploma y Roche sale de compras.
May 07, 2026
Novel Exon skipping Therapies for Patients with DMD: An Industry Update from Entrada Therapeutics
Apr 15, 2026
How to Invest in Entrada Therapeutics Inc (TRDA) Step by Step
Apr 08, 2026
Community Chat
Ask AI
Try asking